418 related articles for article (PubMed ID: 34556161)
1. Prognostic and predictive biomarker developments in multiple myeloma.
Wallington-Beddoe CT; Mynott RL
J Hematol Oncol; 2021 Sep; 14(1):151. PubMed ID: 34556161
[TBL] [Abstract][Full Text] [Related]
2. The role of circulating miRNAs in multiple myeloma.
Zhang J; Xiao X; Liu J
Sci China Life Sci; 2015 Dec; 58(12):1262-9. PubMed ID: 26607481
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma.
Zhou F; Wang D; Wei W; Chen H; Shi H; Zhou N; Wu L; Peng R
BMC Cancer; 2020 Jan; 20(1):40. PubMed ID: 31948430
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
Garcés JJ; Bretones G; Burgos L; Valdes-Mas R; Puig N; Cedena MT; Alignani D; Rodriguez I; Puente DÁ; Álvarez MG; Goicoechea I; Rodriguez S; Calasanz MJ; Agirre X; Flores-Montero J; Sanoja-Flores L; Rodriguez-Otero P; Rios R; Martinez-Lopez J; Millacoy P; Palomera L; Del Orbe R; Pérez-Montaña A; El Omri H; Prosper F; Mateos MV; Rosiñol L; Blade J; Lahuerta JJ; Orfao A; Lopez-Otin C; San Miguel JF; Paiva B;
Leukemia; 2020 Nov; 34(11):3007-3018. PubMed ID: 32475991
[TBL] [Abstract][Full Text] [Related]
5. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.
Landgren O; Morgan GJ
Clin Cancer Res; 2014 Feb; 20(4):804-13. PubMed ID: 24270684
[TBL] [Abstract][Full Text] [Related]
6. Relevant prognostic features of multiple myeloma and the new International Staging System.
Gertz MA
Leuk Lymphoma; 2007 Mar; 48(3):458-68. PubMed ID: 17454585
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding prognosis in myeloma.
Smith D; Yong K
Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers in multiple myeloma.
Levin A; Hari P; Dhakal B
Transl Res; 2018 Nov; 201():49-59. PubMed ID: 30301522
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B; Caetano J; Barahona F; Lopes R; Carneiro E; Costa-Silva B; João C
J Mol Med (Berl); 2020 Apr; 98(4):513-525. PubMed ID: 32246161
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.
Greipp PR
Blood Rev; 1989 Dec; 3(4):222-36. PubMed ID: 2482097
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
14. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
Yang Q; Li K; Li X; Liu J
Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
[No Abstract] [Full Text] [Related]
15. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
[TBL] [Abstract][Full Text] [Related]
16. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers in Multiple Myeloma: A review.
Gupta N; Sharma A; Sharma A
Clin Chim Acta; 2020 Apr; 503():45-53. PubMed ID: 31901479
[TBL] [Abstract][Full Text] [Related]
18. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma.
Valcárcel LV; Amundarain A; Kulis M; Charalampopoulou S; Melnick A; San Miguel J; Martín-Subero JI; Planes FJ; Agirre X; Prosper F
Leukemia; 2021 Oct; 35(10):3012-3016. PubMed ID: 33972667
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.
Soliman AM; Das S; Teoh SL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097
[TBL] [Abstract][Full Text] [Related]
20. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
